Selegiline is a centrally acting, selective, irreversible monamine oxidase-B inhibitor that is FDA-approved for the treatment of canine cognitive dysfunction and pituitary-dependent Cushing's disease in dogs. In humans, it is approved for use as an adjunct for the treatment of Parkinson's disease.
